Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP

Click for more information

0.00%

20.5¢ raptor resources limited

I think you need to use more question marks, to emphasis the...

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 520 Last

Share
Profile

Follow
Levelgrinder

1,612 Posts.

245

15/08/17

21:08

Post #: 26515977
Share

Originally posted by AlCp ↑

I agree, the double blind and randomize study is the FDA standard, but for one last time, the study/trial in Australia involves them enrolling random patient, the patient cough (they and the tester don't know if they have respiratory disease), and the application diagnosis it (either correctly or incorrectly) or was the study the other way around the patient has the disease, they cough (i.e. this could involve you so-called sham coughs as a placebo), and then the apps try to match it???? That's not how it works is it??????

But did it failed due to the quality of the data gathered is the question here........as mentioned by RAP????? Are you saying something is "dodgy" with what they are saying????

Expand

I think you need to use more question marks, to emphasis the point you are making. Just my opinion, do your own research etc.

RAP Price at posting: 7.6¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

OJC

SPC to merge with Original Juice Co and Nature One Dairy

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 57 more messages in this thread...

First 520 Last

Add RAP (ASX) to my watchlist